Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
Looking for the most active stocks in the S&P500 index on Friday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market.
The financial markets are currently navigating a turbulent sea of uncertainty, grappling with the profound implications of significantly delayed economic reports. As of November 25, 2025, the aftershocks of a recent 43-day U.S. government shutdown, which concluded on November 12th, have created an unprecedented "information vacuum." This scarcity of
Although the U.S. stock market is trading close to an all-time high, its dividend yield is approaching a 20-year low, and that's creating a challenge for income-oriented investors.
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
Copenhagen, Denmark – November 24, 2025 – Novo Nordisk's (CPH: NOVO B) stock experienced a significant and immediate downturn today, plummeting by over 10% in early trading, following the announcement of disappointing results from its highly anticipated late-stage clinical trials for an Alzheimer's disease drug. The trials, which tested an oral formulation
NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant (ARV-471) have been accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12, 2025 in San Antonio, Texas. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader which is being developed with Pfizer Inc. (NYSE: PFE) as a potential monotherapy for estrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer with estrogen receptor 1 (ESR1) mutations in the second line-plus setting.* Ongoing studies are also evaluating vepdegestrant as a monotherapy and as part of combination therapy for ER+/HER2- breast cancer.
